Status Topic selection
Technology type Medicine
Decision Awaiting decision
ID number 6403

Provisional Schedule

Committee meeting 02 December 2025

Project Team

Project lead Jeremy Powell

Email enquiries

Stakeholders

Companies sponsors GlaxoSmithKline (niraparib)
Others Department of Health and Social Care
  NHS England
Patient carer groups Black Health Agency for Equality
  Cancer 52
  Cancer Black Care
  Eve Appeal
  Go Girls
  Helen Rollason Cancer Charity
  Independent Cancer Patients Voice
  Macmillan Cancer Support
  Maggie’s Centres
  Marie Curie
  Ovacome
  Ovarian Cancer Action
  Robin Cancer Trust
  South Asian Health Foundation
  Specialised Healthcare Alliance
  Target Ovarian Cancer
  Tenovus Cancer Care
  Wellbeing of Women
  Women’s Health Concern
Professional groups Association of Cancer Physicians
  British Geriatrics Society
  British Gynaecological Cancer Society
  British Institute of Radiology
  British Psychosocial Oncology Society
  British Society of Urogynaecology
  Cancer Research UK
  National Forum of Gynaecological Oncology Nurses
  Royal College of General Practitioners
  Royal College of Nursing
  Royal College of Obstetricians & Gynaecologists
  Royal College of Pathologists
  Royal College of Physicians
  Royal College of Radiologists
  Royal Pharmaceutical Society
  Royal Society of Medicine
  Society and College of Radiographers
  UK Clinical Pharmacy Association
  UK Oncology Nursing Society
Assessment group BMJ Technology Assessment Group
Associated public health groups Public Health Wales
  UK Health Security Agency
Comparator companies AstraZeneca (olaparib)
  Celltrion Healthcare (bevacizumab)
  Clovis Oncology (rucaparib)
  Dr. Reddy's Laboratories (bevacizumab)
  Organon Pharma (bevacizumab)
  Pfizer (bevacizumab)
  Roche (bevacizumab)
  Thornton & Ross (bevacizumab)
  Zentiva (bevacizumab)
  Pharmaand GmbH (rucaparib)
General commentators All Wales Therapeutics and Toxicology Centre
  Allied Health Professionals Federation
  Board of Community Health Councils in Wales
  British National Formulary
  Care Quality Commission
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  National Association of Primary Care
  National Pharmacy Association
  NHS Confederation
  Scottish Medicines Consortium
  Welsh Government
  Welsh Health
Relevant research groups Cochrane Gynaecological Cancer Group
  Cochrane UK
  Genomics England
  Institute of Cancer Research
  MRC Clinical Trials Unit
  National Cancer Research Institute
  National Institute for Health Research

Timeline

Key events during the development of the guidance:

Date Update
12 May 2025 Invitation to participate
14 March 2025 - 11 April 2025 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on how we select topics for development, please see our page about prioritising our guidance topics